02:10 , Feb 14, 2017 |  BioCentury  |  Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

Ex-SASP-erating cancer

German researchers have identified a hypermetabolic phenotype in senescent tumor cells that exerts tumorigenic effects on other cells in the tumor microenvironment. 1 Although the team showed that small molecule inhibitors of the phenotype reduced...
08:00 , Nov 15, 2010 |  BioCentury  |  Emerging Company Profile

VCN: Anti-tumor Ad-vantages

Pancreatic cancer is highly resistant to drugs because about 80% of the tumor is stroma - normal fibrous and connective tissues that support cancer cell growth and invasion - that compounds cannot penetrate efficiently. To...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Company News

Debiopharm, H. Lee Moffitt Cancer Center & Research Institute deal

Debiopharm received exclusive, worldwide rights to develop and commercialize the institute's small molecule inhibitor of the interaction between Raf-1 ( CRAF , RAF ) and retinoblastoma protein , now called Debio 0928 . The compound...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

Seliciclib: Phase I data

A Phase I trial showed that 7 of 14 evaluable patients had clinical evidence of tumor shrinkage, defined as a >25% reduction in palpable cervical lymph nodes. One patient had a reduction in nasopharyngeal tumor...
08:00 , Feb 21, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Myelodysplastic syndromes (MDS) Retinoblastoma protein (Rb) Studies in mice suggest that manipulating Rb expression in hematopoietic cells could be a strategy...
07:00 , Jun 10, 2002 |  BC Week In Review  |  Clinical News

Titan preclinical data

In a mouse model of human head and neck squamous cell carcinoma, AD-RB94 plus cisplatin significantly reduced tumor growth without toxicity compared to a toxic dose of cisplatin alone. In addition, the combination therapy significantly...
08:00 , Mar 30, 1998 |  BC Week In Review  |  Company News

University of Toronto other research news

Canadian researchers reported in The New England Journal of Medicine that mutations in a tumor suppressor gene occur in some patients with multiple primary melanomas. These patients have repeat melanoma of the same tissue type....